Table of Contents Table of Contents
Previous Page  86 / 88 Next Page
Information
Show Menu
Previous Page 86 / 88 Next Page
Page Background

84

NCCN Guidelines for Patients

®

:

Brain Cancer – Gliomas, Version 1.2016

Index

Index

alternating electric field therapy

28, 42–46

astrocytomas

14, 20, 32–46

biopsy

19, 32–33, 36–37, 40–41, 48–49, 52, 60, 62

brain PET

18, 39, 45, 56

cancer grade

12–15, 32, 35, 37, 41, 46, 48, 51, 53,

60

chemotherapy

21, 24–27, 30 ,33–35, 37–40, 44–46,

48–52, 55–57, 64–66

clinical trial

28–30, 33, 35, 37, 39–40, 45, 48–49,

51–52, 56, 65

computed tomography

18, 21, 32, 35, 37, 39, 41, 45,

48, 51, 53, 55, 57, 60, 65

ependymomas

59–66

external beam radiation therapy

21–23, 33–37,

42–43, 48–51, 54–55, 62–65

glioblastomas

21, 28, 40–46

gliosarcomas

40–45

magnetic resonance imaging

17–18, 30, 32, 34–35,

37–39, 41, 44–46, 48, 50–51, 53–57, 60–61, 63–66

molecular testing 20, 57

MR perfusion

17, 39, 45, 56

MR spectroscopy

17, 39, 45, 56

NCCN Member Institutions

82

NCCN Panel Members

81

observation

32–33, 35, 48–49, 51, 62–63

oligoastrocytomas

20, 48–57

oligodendrogliomas

20–21, 24, 48–57

radiation therapy

21–23, 30, 32, 34–35, 38–39,

44–46, 50–51, 54–57, 62–63, 65–66

resection

18–19, 32–33, 36–37 40–41, 48–49, 52–53,

60, 62–63

supportive care

29–30, 34–39, 42–46, 50–51, 54–57,

64–66

symptoms

14–15, 17, 19, 23, 29–30, 32–33, 35–40,

44–46, 48–49, 51–52, 55–57, 65

targeted therapy

25, 27, 30, 39, 45, 56